1M. Dubois,F. Pattou,J. Kerr-Conte,V. Gmyr,B. Vandewalle,P. Desreumaux,J. Auwerx,K. Schoonjans,J. Lefebvre. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in normal human pancreatic islet cells[J] 2000,Diabetologia(9):1165～1169
2L. Mykk?nen,D. J. Zaccaro,C. N. Hales,A. Festa,S. M. Haffner. The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed Type II diabetes: the Insulin Resistance Atherosclerosis Study[J] 1999,Diabetologia(9):1060～1066
3J. D. McGarry,R. L. Dobbins. Fatty acids, lipotoxicity and insulin secretion[J] 1999,Diabetologia(2):128～138
4S. M. Haffner,C. Gonzalez,L. Mykk?nen,M. Stern. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study[J] 1997,Diabetologia(7):830～837
5Dr. K. Masuda,Y. Okamoto,Y. Tsuura,S. Kato,T. Miura,K. Tsuda,H. Horikoshi,H. Ishida,Y. Seino. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide[J] 1995,Diabetologia(1):24～30
6Dr. W. K. Ward,E. C. LaCava,T. L. Paquette,J. C. Beard,B. J. Wallum,D. Porte. Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance[J] 1987,Diabetologia(9):698～702
